A. | Culture results |
|---|
| | Pediatric | Adult |
|---|
| | MRSA% | Other result% | MRSA% | Other result% |
|---|
Anti-MRSA therapy only | 52.6 | 47.4 | 34.5 | 65.5 |
B
| | | | |
| |
Culture results
|
| |
Pediatric
|
Adult
|
MSSA%
|
Other result%
|
MSSA%
|
Other result%
|
Anti-MSSA therapy only | 37.5 | 72.5 | 35 | 65 |
C.
| | | | |
| |
Culture results
|
| |
Pediatric
|
Adult
|
MRSA%
|
MSSA%
|
Other result%
|
MRSA%
|
MSSA%
|
Other result%
|
Double Coverage | 62.5 | 37.5 | 0.0 | 44.3 | 21.5 | 34.2 |
- MSSA = methicillin-sensitive S. aureus; MRSA = methicillin-resistant S. aureus.
-
NB : Patients (63 pediatric, 189 adult) with skin and soft tissue infections (SSTIs) that were cultured in the ED and who received antibiotics are shown, with pediatric and adult patients considered separately. Tables are separated by empiric therapy given and the culture result targeted. 4A: Patients who were treated with empiric anti-MRSA antibiotics only. 4B: Patients who were treated with empiric anti-MSSA antibiotics only. 4C: Patients who were treated with double coverage (treatment with two or more antibiotics with gram-positive coverage).
- Anti-MRSA antibiotics include antibiotics typically active against community-acquired (CA-) MRSA: trimethoprim-sulfamethoxazole, tetracycline, doxycycline, clindamycin, rifampin, linezolid or vancomycin. Anti-MSSA antibiotics include anti-staphylococcal antibiotics typically ineffective against CA-MRSA (penicillins, cephalosporins, macrolides, fluoroquinolones).
